Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

But the European drugs are extremely popular here in the U.S. Wegovy – the version of the drug that’s FDA-approved to treat obesity – has about 200,000 weekly prescriptions in the U.S., according to ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Global pharmaceutical stocks dropped after President Trump wrote to 17 companies asking them to [cut the costs of drugs]( ...